Cytokinetics logo

Cytokinetics Stock

StockStock
ISIN: US23282W6057
Ticker: CYTK
US23282W6057
CYTK

Price

Frequently asked questions

What is Cytokinetics's market capitalization?

The market capitalization of Cytokinetics is $6.63B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Cytokinetics?

Cytokinetics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.388. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Cytokinetics's stock?

Currently, 17 analysts cover Cytokinetics's stock, with a consensus target price of $83.75. Analyst ratings provide insights into the stock's expected performance.

What is Cytokinetics's revenue over the trailing twelve months?

Over the trailing twelve months, Cytokinetics reported a revenue of $3.22M.

What is the EBITDA for Cytokinetics?

Cytokinetics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$511.14M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Cytokinetics?

Cytokinetics has a free cash flow of -$407.05M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Cytokinetics's stock?

The 5-year beta for Cytokinetics is 0.82. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Cytokinetics have, and what sector and industry does it belong to?

Cytokinetics employs approximately 423 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Cytokinetics's shares?

The free float of Cytokinetics is 116.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$6.63B

5Y beta

 
0.82

EPS (TTM)

 
-$5.388

Free Float

 
116.44M

Revenue (TTM)

 
$3.22M

EBITDA (TTM)

 
-$511.14M

Free Cashflow (TTM)

 
-$407.05M

Pricing

1D span
$55.73$57.96
52W span
$30.68$110.25

Analyst Ratings

The price target is $83.75 and the stock is covered by 17 analysts.

Buy

14

Hold

3

Sell

0

Information

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

423

Biotechnology & Drugs

Health Care

Identifier

ISIN

US23282W6057

Primary Ticker

CYTK

Knockouts

Join the conversation